Rheumatology
579 articles · 21 journals
Journals in this subcategory (21)
- Annals of the Rheumatic Diseases · Elsevier (86)
- Seminars in Arthritis and Rheumatism · Elsevier (76)
- Osteoarthritis and Cartilage · Elsevier (57)
- Best Practice & Research Clinical Rheumatology · Elsevier (52)
- The Lancet Rheumatology · Elsevier (47)
- Reumatología Clínica · Elsevier (45)
- Rheumatic Disease Clinics of North America · Elsevier (37)
- Arthritis Care and Research · Wiley (33)
- Joint Bone Spine · Elsevier (31)
- Revue du Rhumatisme · Elsevier (31)
- International Journal of Rheumatic Diseases · Wiley (28)
- Rheumatology and Autoimmunity · Wiley (21)
- The Egyptian Rheumatologist · Elsevier (16)
- ACR Open Rheumatology · Wiley (11)
- Nature Reviews Rheumatology · Springer Nature (8)
- Advances in Rheumatology · Springer Nature (0)
- Arthritis Research & Therapy · Springer Nature (0)
- BMC Rheumatology · Springer Nature (0)
- Clinical Rheumatology · Springer Nature (0)
- Current Rheumatology Reports · Springer Nature (0)
- Egyptian Rheumatology and Rehabilitation · Springer Nature (0)
- Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design
- Ultrasound-defined presynovitis is associated with progression to clinical arthritis in ACPA-positive individuals at risk of rheumatoid arthritis: longitudinal insights from the Karolinska Risk-RA cohort
- A global OMERACT ultrasound joint damage scoring system (GLODS) in rheumatoid arthritis
- Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- Rheumatoid arthritis susceptibility genes show pathotype-specific expression in synovial tissue of patients with early treatment-naïve RA
- Impact of disease activity on bone density, microarchitecture, and biomechanical properties in rheumatoid and psoriatic arthritis over 7 years
- Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries
- Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals
- Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial
- Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series
- High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis
- Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc)
- Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial
- Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups
- Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
- Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease
- Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD)
- A novel STAT4 gain-of-function variant defines a monogenic form of juvenile-onset systemic lupus erythematosus
- Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma
- Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series’ by Siegert et al
- Response to a Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis – a case series’
- Correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
- Response to correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
- Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al
- Response to correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Zhang et al
- Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al
- Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’
- Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947
- Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8
- Nicotinamide N-methyltransferase drives fibroblast activation and skin fibrosis in systemic sclerosis